<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412503</url>
  </required_header>
  <id_info>
    <org_study_id>CSET 1197</org_study_id>
    <nct_id>NCT00412503</nct_id>
  </id_info>
  <brief_title>Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents</brief_title>
  <official_title>Phase 1 Study of Temozolomide Associated With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      Long term survival can now be achieved in 75% of cases of pediatric cancers. However, some&#xD;
      types of tumors (ie CNS tumors) or advanced stages (metastatic sarcomas/neuroblastomas)&#xD;
      cannot be cured by any treatment. Thus, evaluation of new drugs or combinations are strongly&#xD;
      needed. The recommended doses have been defined in children for TMZ (200 mg/m2/d x 5 d) and&#xD;
      TPT (1.5 mg/m2/d x 5 d). Some preclinical and clinical studies have shown activity of both&#xD;
      drugs in some pediatric cancers. Nevertheless, the association of the two drugs has never&#xD;
      been evaluated. The study aims to determine Maximum Tolerated Dose and dose limiting&#xD;
      toxicities of each drug when associated and to assess efficacy of the combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To determine MTD and DLT of each drug</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate Pharmacokinetic of Temozolomide and Topotecan when associated</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of the association</measure>
  </secondary_outcome>
  <condition>Refractory Tumors</condition>
  <condition>Malignant Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan, Temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically documented malignant tumor&#xD;
&#xD;
          -  refractory or relapsing after conventional treatments and for which there is no&#xD;
             curative treatment available&#xD;
&#xD;
          -  life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  no significant co-morbidity (NCI-CTC &lt; 2)&#xD;
&#xD;
          -  No organ toxicity&#xD;
&#xD;
          -  no chemotherapy within the 4 previous weeks, 6 weeks for nitrosurea or radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensibility to Topotecan and/or Temozolomide or to one of their compounds&#xD;
&#xD;
          -  Hypersensibility to Dacarbazine (DTIC)&#xD;
&#xD;
          -  Galactosaemia, Glucose and galactose malabsorption syndrom, deficiency in lactase&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Herve Rubie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ille de France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>December 15, 2006</study_first_submitted>
  <study_first_submitted_qc>December 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <last_update_submitted>August 6, 2009</last_update_submitted>
  <last_update_submitted_qc>August 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

